ACHN—To keep this thread in perspective: My view is that IP protection isn’t the biggest risk for ACHN; rather, the biggest risk is that ACH-3422 simply doesn’t work as well as Sovaldi (or other HCV nukes in development).
The ACH-3422 monotherapy data to be reported at AASLD won’t tell us as much as some investors think about whether the drug ultimately succeeds or fails.
News 
Market Data 
Discover 
